Symphogen A/S Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology Association
6/10/2011 10:57:56 AM
COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen announced today preliminary data from a phase 2 clinical trial with rozrolimupab (SYM001) in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP). The study showed rozrolimupab is well tolerated with no unexpected toxicities and shows preliminary signs of clinical and biological activity by decreasing haemoglobin values.
comments powered by